J3401 Insurance Policy Changes

HCPCS J3401 is officially defined as "Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml." HCPCS J3401 is referenced in 2 tracked payer policy changes from Texas Medicaid and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3401 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.